| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -8.2% | -21.1% |
| Cost of Revenue | $919K | +31.1% | +57.2% |
| R&D Expense | $906K | +49.5% | +238.0% |
| SG&A Expense | $1.5M | -9.4% | +312.6% |
| Operating Income | -$2.1M | -29.4% | -634.1% |
| Pre-tax Income | -$1.9M | -24.1% | +36.0% |
| Net Income | -$1.9M | -24.1% | +36.0% |
| EPS (Basic) | -$0.11 | -22.2% | +54.2% |
| EPS (Diluted) | -$0.11 | -22.2% | +54.2% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $38.6M | +48.8% | +1159.3% |
| Accounts Receivable | $1.0M | -19.9% | -24.5% |
| Current Assets | $40.3M | +0.1% | +788.8% |
| Total Assets | $42.6M | -0.2% | +529.9% |
| Current Liabilities | $825K | +7.4% | +68.8% |
| Total Liabilities | $1.8M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.1M | -30.8% | — |
| Capital Expenditures | $241K | +14.8% | — |
| Investing Cash Flow | -$241K | -14.8% | — |
| Financing Cash Flow | $24.1M | +3.0% | — |
| Free Cash Flow | -$1.3M | -27.5% | — |
| -77.3% |
| Stockholders' Equity | $40.8M | -0.2% | +4053.4% |